Stock listing

BMV:ACAD ACADIA Pharmaceuticals Inc. Acciones

Mexican listing (BMV) of ACADIA Pharmaceuticals Inc. · home listing NASDAQ:ACAD

Follow ACADIA Pharmaceuticals Inc. into a list and get an email when it puts out news.

Home listing price · NASDAQ:ACAD

$17.11 USD -0.72 (-4.0%)

Close on Nov 20, 2026 · This listing has no price on 6ix; the price shown is the home listing's, NASDAQ:ACAD

Past year -25.3% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$17.05 – $17.79 USDNov 20, 2026
Volume
1.90M sharesNov 20, 2026
Market cap
$2.96B USDAt the close on Nov 20, 2026 · price × 172.8M shares outstanding
52-week range
$15.86 – $30.96 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$47.08M USDMedian day 1.63M shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
ACADIA Pharmaceuticals Inc. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:ACAD · Home$17.11 USD-0.72 (-4.0%)1,903,306$17.47$17.79$17.05$17.83Close on Nov 20, 2026
Frankfurt:DR6€15.81 EUR-0.495 (-3.0%)—€15.81€15.81€15.81€16.31Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:ACAD · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$17.11-0.72-4.0%$17.47$17.79$17.051,903,306
$17.83-0.49-2.7%$18.10$18.49$17.831,895,555
$18.32-0.35-1.9%$18.54$18.73$17.941,535,421
$18.67-0.08-0.4%$18.84$19.44$18.592,116,858
$18.75+0.61+3.4%$18.12$18.76$18.001,785,088
$18.14-0.23-1.3%$18.22$18.37$17.931,934,198
$18.37+0.09+0.5%$18.13$18.58$17.902,395,219
$18.28+1.78+10.8%$16.41$18.39$16.386,354,161
$16.50-4.73-22.3%$21.41$21.66$15.8612,150,930
$21.23-0.010.0%$21.00$21.45$20.591,770,851
$21.24-0.23-1.1%$21.98$22.63$21.146,027,494
$21.47+0.90+4.4%$21.18$21.54$20.514,719,961
$20.57+0.10+0.5%$20.50$20.82$20.451,709,205
$20.47-0.12-0.6%$20.71$20.76$20.251,384,944
$20.59-0.17-0.8%$20.88$21.01$20.491,137,497
$20.76+0.44+2.2%$20.61$20.88$20.502,193,810
$20.32+0.15+0.7%$20.00$20.35$20.001,336,007
$20.17+0.43+2.2%$19.58$20.29$19.511,332,125
$19.74+0.01+0.1%$19.72$19.89$19.591,229,734
$19.73-0.58-2.9%$20.22$20.25$19.581,066,084
$20.31+0.12+0.6%$20.30$20.50$20.121,229,385
$20.19-0.25-1.2%$20.44$20.57$20.101,409,868
$20.44+0.64+3.2%$20.04$20.49$19.861,675,506
$19.80+0.68+3.6%$19.33$19.84$19.111,298,632
$19.12-0.59-3.0%$19.76$19.76$18.871,672,256
$19.71+0.46+2.4%$19.48$19.88$19.281,767,168
$19.25+0.63+3.4%$18.60$19.28$18.491,642,771
$18.62-0.79-4.1%$19.05$19.10$18.392,140,646
$19.41-0.37-1.9%$19.70$19.87$19.401,184,727
$19.78+0.20+1.0%$19.60$20.05$19.581,470,247
$19.58-0.07-0.4%$19.46$19.79$19.322,006,572
$19.65-0.09-0.5%$19.60$19.80$19.461,784,747
$19.74-0.37-1.8%$20.16$20.36$19.671,666,303
$20.11+0.16+0.8%$20.05$20.45$19.573,152,355
$19.95+0.06+0.3%$20.01$20.24$19.882,564,592
$19.89-0.26-1.3%$19.95$20.19$19.592,731,696
$20.15-0.07-0.3%$20.28$20.70$19.933,134,008
$20.22-0.31-1.5%$20.61$20.61$20.062,515,050
$20.53-0.15-0.7%$20.53$20.63$19.803,522,828
$20.68-1.50-6.8%$22.21$22.21$20.613,364,113
$22.18-3.25-12.8%$24.38$24.38$21.976,761,623
$25.43-0.98-3.7%$26.41$26.51$24.931,306,066
$26.41+0.015+0.1%$26.65$26.86$26.321,472,449
$26.40-0.895-3.3%$27.43$27.43$26.341,351,979
$27.29-0.16-0.6%$27.37$27.48$26.735,482,812
$27.45-0.09-0.3%$27.78$28.06$27.291,307,767
$27.54+0.78+2.9%$26.75$27.60$26.661,405,152
$26.76-0.76-2.8%$27.51$27.51$26.641,109,419
$27.52-0.31-1.1%$28.00$28.10$27.381,628,513
$27.83+0.09+0.3%$27.98$28.24$27.741,172,902
$27.74+0.06+0.2%$27.63$27.86$27.361,014,565
$27.68+0.10+0.4%$27.44$27.95$27.401,293,919
$27.58-0.44-1.6%$27.63$28.09$27.101,457,760
$28.02+0.16+0.6%$27.77$28.19$27.651,682,950
$27.86-1.07-3.7%$29.00$29.07$27.621,849,411
$28.93+0.04+0.1%$29.10$29.75$28.881,555,986
$28.89-0.02-0.1%$28.84$29.30$28.51830,928
$28.91-0.20-0.7%$29.05$29.12$28.581,035,961
$29.11-0.62-2.1%$29.51$29.73$29.021,529,974
$29.73+0.15+0.5%$29.26$29.83$29.15879,365
$29.58-0.99-3.2%$30.36$30.38$29.281,336,189
$30.57+0.92+3.1%$30.14$30.76$29.851,523,784
$29.65+0.15+0.5%$29.50$29.78$29.151,489,609
$29.50+0.46+1.6%$29.08$29.62$28.801,093,516
$29.04-1.17-3.9%$30.00$30.00$28.951,318,712
Ticker
BMV:ACAD
Asset type
Stock
Sector
Health care
Industry
Pharmaceuticals
Exchange
BMV
Currency
MXN

What changed lately

Latest news

All ACADIA Pharmaceuticals Inc. news

ACADIA Pharmaceuticals Inc. on 6ix

Sector
Health care
Industry
Pharmaceuticals
News releases
30 in the last 12 months · 200 in all · newest Nov 17, 2026 · oldest 2019
Calls
27 calls with a replay · 27 with a transcript · latest Nov 4, 2026
Decks
32 decks · latest Nov 4, 2026

Where ACADIA Pharmaceuticals Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:ACAD · Home listingNASDAQUnited StatesUSD
gettex:DR6gettexGermanyEUR
Tradegate:DR6TradegateGermanyEUR
BMV:ACAD · This pageBMVMexicoMXN
LS Exchange:603035LS ExchangeGermanyEUR
Lang & Schwarz:603035Lang & SchwarzGermanyEUR
Frankfurt:DR6FrankfurtGermanyEUR
BIVA:ACADBIVAMexicoMXN
BOATS:ACADBOATSUnited StatesUSD
LSE:0A4WLSEUnited KingdomUSD
Dusseldorf:DR6DusseldorfGermanyEUR
Munich:DR6MunichGermanyEUR
Stuttgart:DR6StuttgartGermanyEUR

Valuation

P/E 8.2× against a median of 16.5×: 2nd lowest of 8 Pharmaceuticals companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
$2.05B USD
P/E
8.2×
EV/sales
1.7×
EV/EBITDA
15.5×
Price/book
2.1×
Gross margin
90.5%
Operating margin
10.2%
Net margin
30.1%
Debt to equity
0.1×
Beta vs S&P 500
0.40

Pharmaceuticals: the 10 companies nearest in size, of 492 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
ACADIA Pharmaceuticals Inc. · NASDAQ:ACADUS$2.96BUS$2.05B8.2×1.7×15.5×2.1×30.1%0.1×0.40
Hualan Biological Engineering Inc. Class A · SZSE:002007US$3.13BUS$2.62B35.6×4.6×n/a2.0×15.4%0.0×n/a
Xeris Biopharma Holdings, Inc. · NASDAQ:XERSUS$3.10BUS$3.16Bn/a8.6×58.9×63.5×−1.8%3.9×0.11
Bausch Health Companies Inc. · TSX:BHCUS$3.08BUS$21.23Bn/a1.9×n/an/a−7.6%n/a0.65
Rubicon Research Limited · NSE:RUBICONUS$3.07BUS$3.05B98.7×14.6×62.8×22.1×14.9%0.1×n/a
Jilin Aodong Pharmaceutical Group Co., Ltd. Class A · SZSE:000623US$2.97BUS$2.55B6.6×7.6×n/a0.6×133.7%0.0×n/a
ADMA Biologics Inc · NASDAQ:ADMAUS$2.92BUS$2.99B16.0×5.8×12.0×6.7×35.1%0.5×0.05
Telix Pharmaceuticals Limited · ASX:TLXUS$2.90BUS$3.22Bn/a4.0×63.0×5.9×−0.9%1.2×n/a
Chengdu Kanghong Pharmaceutical Group Co., Ltd. Class A · SZSE:002773US$2.89BUS$1.93B21.1×3.1×n/a2.0×22.1%0.0×n/a
China Medical System Holdings Ltd. · HKEX:867US$2.86BUS$2.14B12.8×1.7×7.7×1.1×18.1%0.1×n/a
Joincare Pharmaceutical Group Industry Co., Ltd. Class A · SSE:600380US$2.79BUS$1.15B16.5×0.6×n/a1.3×8.4%0.1×n/a
Median of the othersUS$2.95BUS$2.81B16.5×4.3×58.9×2.0×15.2%0.1×0.11

Forecasts

10 strong buy · 4 buy · 5 hold · 1 strong sell · Analysts' consensus from EODHD, read Nov 19, 2026. Not 6ix's view and not investment advice.

Price target
30.32 USD · Analysts' mean
EPS, year to Dec 2026
0.77 · 13 analysts
Revenue, year to Dec 2026
1.28B · 19 analysts

Team and board

Officers

OfficerRole
Catherine Owen AdamsChief Executive Officer
Mark SchneyerChief Financial Officer
Jennifer J. RhodesChief Legal Officer and Secretary
Carl SegerstromChief People Officer
Konstantina KatchevesChief Business and Strategy Officer
Scott CenciChief Information and Data Officer

Board

DirectorRole
Stephen BiggarChairman
Adora NduDirector
Edmund HarriganDirector
Elizabeth GarofaloDirector
James DalyDirector
Jonathan M. PooleDirector
Julian BakerDirector
Laura BregeDirector

Events

Calls

CallWhenStatus
ACADIA Pharmaceuticals (NASDAQ:ACAD) Q3 2026 Earnings CallWed, Nov 04, 2026 · 4:30 PM ETReplay
ACADIA Pharmaceuticals (NASDAQ:ACAD) Q2 2026 Earnings CallTue, Aug 04, 2026 · 4:30 PM ETReplay
ACADIA Pharmaceuticals (NASDAQ:ACAD) Q1 2026 Earnings CallWed, May 06, 2026 · 4:30 PM ETReplay
ACADIA Pharmaceuticals (NASDAQ:ACAD) Q4 2025 Earnings CallWed, Feb 25, 2026 · 4:30 PM ETReplay
ACADIA Pharmaceuticals (NASDAQ:ACAD) Q3 2025 Earnings CallWed, Nov 05, 2025 · 4:30 PM ETReplay
ACADIA Pharmaceuticals (NASDAQ:ACAD) Q2 2025 Earnings CallWed, Aug 06, 2025 · 4:30 PM ETReplay
ACADIA Pharmaceuticals (NASDAQ:ACAD) Q1 2025 Earnings CallWed, May 07, 2025 · 4:30 PM ETReplay
ACADIA Pharmaceuticals (NASDAQ:ACAD) Q4 2024 Earnings CallWed, Feb 26, 2025 · 4:30 PM ETReplay
ACADIA Pharmaceuticals (NASDAQ:ACAD) Q3 2024 Earnings CallWed, Nov 06, 2024 · 4:30 PM ETReplay
ACADIA Pharmaceuticals (NASDAQ:ACAD) Q2 2024 Earnings CallTue, Aug 06, 2024 · 4:30 PM ETReplay
All 27 calls
CallWhenStatus
ACADIA Pharmaceuticals (NASDAQ:ACAD) Q1 2024 Earnings CallWed, May 08, 2024 · 4:30 PM ETReplay
ACADIA Pharmaceuticals (NASDAQ:ACAD) Q4 2023 Earnings CallTue, Feb 27, 2024 · 4:30 PM ETReplay
ACADIA Pharmaceuticals (NASDAQ:ACAD) Q3 2023 Earnings CallThu, Nov 02, 2023 · 4:30 PM ETReplay
ACADIA Pharmaceuticals (NASDAQ:ACAD) Q2 2023 Earnings CallWed, Aug 02, 2023 · 4:30 PM ETReplay
ACADIA Pharmaceuticals (NASDAQ:ACAD) Q1 2023 Earnings CallMon, May 08, 2023 · 4:30 PM ETReplay
ACADIA Pharmaceuticals (NASDAQ:ACAD) Q4 2022 Earnings CallMon, Feb 27, 2023 · 4:30 PM ETReplay
ACADIA Pharmaceuticals (NASDAQ:ACAD) Q3 2022 Earnings CallWed, Nov 02, 2022 · 4:30 PM ETReplay
ACADIA Pharmaceuticals (NASDAQ:ACAD) Q2 2022 Earnings CallMon, Aug 08, 2022 · 4:30 PM ETReplay
ACADIA Pharmaceuticals (NASDAQ:ACAD) Q1 2022 Earnings CallWed, May 04, 2022 · 4:30 PM ETReplay
ACADIA Pharmaceuticals (NASDAQ:ACAD) Q4 2021 Earnings CallMon, Feb 28, 2022 · 4:30 PM ETReplay
ACADIA Pharmaceuticals (NASDAQ:ACAD) Q3 2021 Earnings CallMon, Nov 08, 2021 · 4:30 PM ETReplay
ACADIA Pharmaceuticals (NASDAQ:ACAD) Q2 2021 Earnings CallWed, Aug 04, 2021 · 4:30 PM ETReplay
ACADIA Pharmaceuticals (NASDAQ:ACAD) Q1 2021 Earnings CallWed, May 05, 2021 · 5:00 PM ETReplay
ACADIA Pharmaceuticals (NASDAQ:ACAD) Q4 2020 Earnings CallWed, Feb 24, 2021 · 4:30 PM ETReplay
ACADIA Pharmaceuticals (NASDAQ:ACAD) Q3 2020 Earnings CallWed, Nov 04, 2020Replay
ACADIA Pharmaceuticals (NASDAQ:ACAD) Q2 2020 Earnings CallWed, Aug 05, 2020Replay
ACADIA Pharmaceuticals (NASDAQ:ACAD) Q1 2020 Earnings CallThu, May 07, 2020Replay

Results days

QuarterResultsShare move
Q3 2026Nov 4, 2026 · After close−1.1%
Q2 2026Aug 4, 2026 · After close+6.1%
Q1 2026May 6, 2026 · After close+5.0%
Q4 2025Mar 2, 2026−8.4%
Q3 2025Nov 5, 2025 · After close−3.0%
Q2 2025Aug 6, 2025 · After close+2.5%
Q1 2025May 7, 2025 · After close+14.3%
Q4 2024Feb 25, 2025 · Before open−2.4%
Q3 2024Nov 6, 2024 · After close+8.9%
Q2 2024Aug 6, 2024 · After close−19.5%
All 20 quarters
QuarterResultsShare move
Q1 2024May 8, 2024 · After close−11.2%
Q4 2023Feb 27, 2024 · After close−9.9%
Q3 2023Nov 2, 2023 · After close+4.7%
Q2 2023Aug 2, 2023 · After close−6.8%
Q1 2023May 8, 2023 · After close−0.6%
Q4 2022Feb 27, 2023 · After close+6.7%
Q3 2022Nov 2, 2022 · After close−7.0%
Q2 2022Aug 8, 2022 · After close−2.4%
Q1 2022May 4, 2022 · After close−5.3%
Q4 2021Feb 28, 2022 · After close−1.3%

Open Events

Decks

DeckKindSlidesDate
Q3 2026 Earnings PresentationEarnings25 slidesNov 4, 2026
Technical Presentation (September 2026)Technical19 slidesSep 24, 2026
Q2 2026 Earnings PresentationEarnings21 slidesAug 4, 2026
Q4 2025 Earnings PresentationEarnings20 slidesFeb 25, 2026
Clinical Trials on Alzheimer's Disease (CTAD) 2026Conference14 slides2026
Q3 2025 Earnings PresentationEarnings17 slidesNov 5, 2025
Q2 2025 Earnings PresentationEarnings20 slidesAug 6, 2025
Q1 2025 Earnings PresentationEarnings19 slidesMay 7, 2025
Q4 2024 Earnings PresentationEarnings25 slidesFeb 26, 2025
Q3 2024 Earnings PresentationEarnings22 slidesNov 6, 2024
All 32 decks
DeckKindSlidesDate
Q2 2024 Earnings PresentationEarnings25 slidesAug 6, 2024
Q1 2024 Earnings PresentationEarnings23 slidesMay 8, 2024
Q4 2023 Earnings PresentationEarnings26 slidesFeb 27, 2024
Q3 2023 Earnings PresentationEarnings24 slidesNov 2, 2023
Q2 2023 Earnings PresentationEarnings25 slidesAug 2, 2023
Q1 2023 Earnings PresentationEarnings22 slidesMay 8, 2023
Q4 2022 Earnings PresentationEarnings30 slidesFeb 27, 2023
Q3 2022 Earnings PresentationEarnings23 slidesNov 2, 2022
Q2 2022 Earnings PresentationEarnings26 slidesAug 8, 2022
Q1 2022 Earnings PresentationEarnings24 slidesMay 4, 2022
Q4 2021 Earnings PresentationEarnings23 slidesFeb 28, 2022
Corporate Update (December 2021)Corporate update18 slidesDec 21, 2021
Q3 2021 Earnings PresentationEarnings27 slidesNov 8, 2021
Q2 2021 Earnings PresentationEarnings26 slidesAug 4, 2021
Q1 2021 Earnings PresentationEarnings25 slidesMay 5, 2021
Corporate Update (April 2021)Corporate update13 slidesApr 5, 2021
Q4 2020 Earnings PresentationEarnings26 slidesFeb 24, 2021
Q3 2020 Earnings PresentationEarnings22 slidesNov 4, 2020
Q2 2020 Earnings PresentationEarnings23 slidesAug 5, 2020
Q1 2020 Earnings PresentationEarnings27 slidesMay 7, 2020
38th Annual J.P. Morgan Healthcare Conference 2020Conference27 slidesJan 13, 2020
Technical Presentation (March 2007)Technical10 slidesMar 19, 2007

Open Decks

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue1.07B957.8M726.4M517.2M484.1M441.8M339.1M223.8M124.9M17.3M
Cost of revenue89.0M81.8M41.6M10.2M19.1M10.2M11.3M12.4M9.08M3.08M
Gross profit982.5M876.0M684.8M507.1M473.3M431.5M327.7M211.4M115.8M14.3M
Research and development328.8M303.2M351.6M361.6M239.4M319.1M240.4M187.2M149.2M99.3M
Selling, general and administrative548.9M488.4M406.6M369.1M396.0M388.7M325.6M265.8M255.1M186.5M
Operating income104.8M230.8M-73.4M-223.6M-170.4M-286.6M-246.5M-247.4M-292.4M-272.8M
Depreciation and amortization871.0K920.0K1.46M2.03M2.24M1.46M1.29M1.53M1.24M843.0K
EBITDA105.7M231.7M-71.9M-221.6M-168.2M-285.1M-245.3M-245.9M-291.2M-272.0M
Interest expense6.61M6.26M8.54M14.9M000
Income before tax138.9M258.1M-51.0M-213.4M-167.5M-281.0M-234.4M-243.9M-288.3M-270.1M
Income tax-252.1M31.6M10.3M2.53M351.0K611.0K876.0K1.26M1.12M1.34M
Net income391.0M226.5M-61.3M-216.0M-167.9M-281.6M-235.3M-245.2M-289.4M-271.4M
Earnings per share, basic2.321.37-0.37-1.34-1.05-1.79-1.60-1.94-2.36-2.34
Earnings per share, diluted2.301.36-0.37-1.34-1.05-1.79-1.60-1.94-2.36-2.34

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents177.7M319.6M188.7M114.8M147.4M326.0M189.7M134.8M69.4M163.6M
Short-term investments642.0M436.4M250.2M302.0M373.3M305.9M507.7M338.8M271.9M365.4M
Receivables121.5M98.7M98.3M62.2M64.4M48.2M35.8M26.1M17.3M5.90M
Inventory111.4M91.7M40.4M11.6M14.1M9.68M6.34M4.07M5.25M4.17M
Current assets1.06B938.3M616.1M507.9M617.8M717.6M760.3M526.1M373.5M547.9M
Property, plant and equipment7.51M4.21M4.61M6.02M8.05M9.16M3.18M3.31M2.66M3.08M
Goodwill100
Total assets1.56B1.19B749.0M587.8M700.1M782.6M783.2M540.2M384.5M561.2M
Accounts payable10.9M16.2M17.5M12.7M6.88M8.49M7.22M3.17M8.79M3.91M
Current liabilities277.1M394.9M254.3M125.6M96.1M106.0M74.8M59.6M49.0M42.6M
Long-term debt00
Total debt52.2M52.0M57.2M62.0M64.4M49.5M9.79M
Total liabilities336.8M455.0M317.2M187.4M159.2M155.6M84.0M61.1M49.2M42.7M
Shareholders' equity1.23B732.8M431.8M400.4M540.9M627.0M699.1M479.1M335.3M518.4M
Shares outstanding170.3M166.7M164.7M162.1M161.0M159.6M155.3M143.9M124.4M121.4M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations109.8M157.7M16.7M-114.0M-125.7M-136.2M-151.1M-167.5M-217.8M-208.4M
Capital spending-4.69M-523.0K-50.0K0-1.12M-7.59M-1.13M-2.10M-812.0K-1.51M
Free cash flow105.1M157.2M16.7M-114.0M-126.8M-143.8M-152.3M-169.6M-218.6M-209.9M
Cash from investing-302.6M-30.5M32.0M73.2M-71.1M192.5M-165.8M-71.5M92.5M-261.9M
Cash from financing49.9M6.84M25.1M8.20M18.2M81.0M371.8M306.6M31.2M533.8M
Dividends paid00
Share buybacks18.2M81.0M371.8M306.6M31.2M518.9M
Change in cash-142.8M133.9M73.8M-32.6M-178.6M137.3M54.9M67.7M-94.1M63.5M

Open Financials

Filings

FilingDateTypeFiled with
SCHEDULE 13G · Big-stake noticeNov 10, 2026Big-stake noticeSEC
10-Q · Quarterly reportNov 4, 2026Quarterly reportSEC
8-K · Current reportNov 4, 2026ResultsSEC
4 · Change in ownershipOct 30, 2026Insider tradeSEC
8-K · Current reportOct 23, 2026Management or board changeSEC
8-K · Current reportSep 24, 2026Current reportSEC
8-K · Current reportSep 11, 2026Current reportSEC
4 · Change in ownershipAug 7, 2026Insider tradeSEC
SCHEDULE 13G · Big-stake noticeAug 7, 2026Big-stake noticeSEC
144 · Notice of proposed saleAug 5, 2026Other filingsSEC
Show 200 filings
FilingDateTypeFiled with
10-Q · Quarterly reportAug 4, 2026Quarterly reportSEC
8-K · Current reportAug 4, 2026ResultsSEC
4 · Change in ownershipJul 31, 2026Insider tradeSEC
4 · Change in ownershipJun 29, 2026Insider tradeSEC
144 · Notice of proposed saleJun 26, 2026Other filingsSEC
S-8 · Registration statement for employee plansJun 10, 2026Offer documentSEC
4 · Change in ownershipJun 2, 2026Insider tradeSEC
4 · Change in ownershipJun 1, 2026Insider tradeSEC
4 · Change in ownershipJun 1, 2026Insider tradeSEC
4 · Change in ownershipJun 1, 2026Insider tradeSEC
4 · Change in ownershipJun 1, 2026Insider tradeSEC
4 · Change in ownershipJun 1, 2026Insider tradeSEC
4 · Change in ownershipJun 1, 2026Insider tradeSEC
8-K · Current reportMay 29, 2026Management or board changeSEC
4 · Change in ownershipMay 27, 2026Insider tradeSEC
144 · Notice of proposed saleMay 26, 2026Other filingsSEC
10-Q · Quarterly reportMay 6, 2026Quarterly reportSEC
8-K · Current reportMay 6, 2026ResultsSEC
4 · Change in ownershipMay 5, 2026Insider tradeSEC
4 · Change in ownershipMay 5, 2026Insider tradeSEC
8-K · Current reportApr 30, 2026Management or board changeSEC
SCHEDULE 13G · Big-stake noticeApr 28, 2026Big-stake noticeSEC
ARS · Annual report to shareholdersApr 23, 2026Annual reportSEC
DEF 14A · Proxy statementApr 23, 2026Meeting noticeSEC
4 · Change in ownershipApr 7, 2026Insider tradeSEC
4 · Change in ownershipApr 7, 2026Insider tradeSEC
4 · Change in ownershipMar 26, 2026Insider tradeSEC
4 · Change in ownershipMar 26, 2026Insider tradeSEC
4 · Change in ownershipMar 26, 2026Insider tradeSEC
4 · Change in ownershipMar 26, 2026Insider tradeSEC
4 · Change in ownershipMar 26, 2026Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMar 26, 2026Big-stake noticeSEC
4 · Change in ownershipMar 20, 2026Insider tradeSEC
3 · Initial statement of ownershipMar 20, 2026Insider tradeSEC
4 · Change in ownershipMar 10, 2026Insider tradeSEC
4 · Change in ownershipMar 10, 2026Insider tradeSEC
4 · Change in ownershipMar 10, 2026Insider tradeSEC
4 · Change in ownershipMar 10, 2026Insider tradeSEC
4 · Change in ownershipMar 10, 2026Insider tradeSEC
4 · Change in ownershipMar 10, 2026Insider tradeSEC
8-K · Current reportMar 4, 2026Management or board changeSEC
SCHEDULE 13D/A · Big-stake notice, amendedFeb 26, 2026Big-stake noticeSEC
10-K · Annual reportFeb 25, 2026Annual reportSEC
8-K · Current reportFeb 25, 2026ResultsSEC
4 · Change in ownershipFeb 10, 2026Insider tradeSEC
8-K · Current reportJan 13, 2026ResultsSEC
4 · Change in ownershipNov 19, 2025Insider tradeSEC
4 · Change in ownershipNov 19, 2025Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 14, 2025Big-stake noticeSEC
4 · Change in ownershipNov 12, 2025Insider tradeSEC
144 · Notice of proposed saleNov 10, 2025Other filingsSEC
10-Q · Quarterly reportNov 5, 2025Quarterly reportSEC
8-K · Current reportNov 5, 2025ResultsSEC
8-K · Current reportNov 3, 2025Management or board changeSEC
4 · Change in ownershipSep 16, 2025Insider tradeSEC
4 · Change in ownershipSep 3, 2025Insider tradeSEC
4 · Change in ownershipAug 19, 2025Insider tradeSEC
144 · Notice of proposed saleAug 18, 2025Other filingsSEC
10-Q · Quarterly reportAug 6, 2025Quarterly reportSEC
8-K · Current reportAug 6, 2025ResultsSEC
8-K · Current reportJun 10, 2025Current reportSEC
4 · Change in ownershipJun 5, 2025Insider tradeSEC
144 · Notice of proposed saleJun 4, 2025Other filingsSEC
4 · Change in ownershipJun 2, 2025Insider tradeSEC
4 · Change in ownershipJun 2, 2025Insider tradeSEC
4 · Change in ownershipJun 2, 2025Insider tradeSEC
4 · Change in ownershipJun 2, 2025Insider tradeSEC
4 · Change in ownershipJun 2, 2025Insider tradeSEC
4 · Change in ownershipJun 2, 2025Insider tradeSEC
4 · Change in ownershipJun 2, 2025Insider tradeSEC
8-K · Current reportMay 29, 2025Meeting outcomeSEC
EFFECT · Notice that a registration is effectiveMay 27, 2025Other filingsSEC
CORRESP · Letter to the SECMay 21, 2025Other filingsSEC
8-K · Current reportMay 20, 2025Material contractSEC
4 · Change in ownershipMay 19, 2025Insider tradeSEC
4 · Change in ownershipMay 19, 2025Insider tradeSEC
144 · Notice of proposed saleMay 16, 2025Other filingsSEC
144 · Notice of proposed saleMay 16, 2025Other filingsSEC
UPLOAD · Letter from the SECMay 14, 2025Other filingsSEC
S-3 · Registration statementMay 9, 2025Offer documentSEC
10-Q · Quarterly reportMay 7, 2025Quarterly reportSEC
8-K · Current reportMay 7, 2025ResultsSEC
4 · Change in ownershipMay 2, 2025Insider tradeSEC
4 · Change in ownershipMay 2, 2025Insider tradeSEC
ARS · Annual report to shareholdersApr 25, 2025Annual reportSEC
DEF 14A · Proxy statementApr 25, 2025Meeting noticeSEC
8-K · Current reportApr 16, 2025Current reportSEC
4 · Change in ownershipApr 8, 2025Insider tradeSEC
4 · Change in ownershipApr 8, 2025Insider tradeSEC
4 · Change in ownershipMar 26, 2025Insider tradeSEC
4 · Change in ownershipMar 26, 2025Insider tradeSEC
4 · Change in ownershipMar 26, 2025Insider tradeSEC
4 · Change in ownershipMar 26, 2025Insider tradeSEC
4 · Change in ownershipMar 26, 2025Insider tradeSEC
4 · Change in ownershipMar 6, 2025Insider tradeSEC
144 · Notice of proposed saleMar 6, 2025Other filingsSEC
10-K · Annual reportFeb 27, 2025Annual reportSEC
8-K · Current reportFeb 26, 2025ResultsSEC
4 · Change in ownershipFeb 25, 2025Insider tradeSEC
4 · Change in ownershipFeb 25, 2025Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 14, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 7, 2025Big-stake noticeSEC
8-K · Current reportDec 11, 2024Acquisition or disposalSEC
4 · Change in ownershipDec 10, 2024Insider tradeSEC
3 · Initial statement of ownershipDec 10, 2024Insider tradeSEC
8-K · Current reportNov 20, 2024Management or board changeSEC
4 · Change in ownershipNov 19, 2024Insider tradeSEC
4 · Change in ownershipNov 19, 2024Insider tradeSEC
4 · Change in ownershipNov 19, 2024Insider tradeSEC
SC 13G/A · Big-stake notice, amendedNov 14, 2024Big-stake noticeSEC
10-Q · Quarterly reportNov 6, 2024Quarterly reportSEC
8-K · Current reportNov 6, 2024ResultsSEC
4 · Change in ownershipOct 15, 2024Insider tradeSEC
4 · Change in ownershipSep 25, 2024Insider tradeSEC
3 · Initial statement of ownershipSep 25, 2024Insider tradeSEC
S-8 · Registration statement for employee plansSep 23, 2024Offer documentSEC
8-K · Current reportSep 23, 2024Management or board changeSEC
4 · Change in ownershipAug 20, 2024Insider tradeSEC
4 · Change in ownershipAug 20, 2024Insider tradeSEC
4 · Change in ownershipAug 20, 2024Insider tradeSEC
S-8 POSAug 20, 2024Offer documentSEC
S-8 POSAug 20, 2024Offer documentSEC
S-8 POSAug 20, 2024Offer documentSEC
S-8 POSAug 20, 2024Offer documentSEC
S-8 POSAug 20, 2024Offer documentSEC
S-8 POSAug 20, 2024Offer documentSEC
S-8 POSAug 20, 2024Offer documentSEC
S-8 POSAug 20, 2024Offer documentSEC
S-8 POSAug 20, 2024Offer documentSEC
4 · Change in ownershipAug 13, 2024Insider tradeSEC
10-Q · Quarterly reportAug 6, 2024Quarterly reportSEC
8-K · Current reportAug 6, 2024ResultsSEC
4 · Change in ownershipJun 11, 2024Insider tradeSEC
4 · Change in ownershipMay 31, 2024Insider tradeSEC
4 · Change in ownershipMay 31, 2024Insider tradeSEC
4 · Change in ownershipMay 31, 2024Insider tradeSEC
4 · Change in ownershipMay 31, 2024Insider tradeSEC
4 · Change in ownershipMay 31, 2024Insider tradeSEC
4 · Change in ownershipMay 31, 2024Insider tradeSEC
4 · Change in ownershipMay 31, 2024Insider tradeSEC
8-K · Current reportMay 29, 2024Management or board changeSEC
S-8 POSMay 29, 2024Offer documentSEC
S-8 POSMay 29, 2024Offer documentSEC
S-8 POSMay 29, 2024Offer documentSEC
S-8 POSMay 29, 2024Offer documentSEC
S-8 POSMay 29, 2024Offer documentSEC
S-8 POSMay 29, 2024Offer documentSEC
S-8 POSMay 29, 2024Offer documentSEC
S-8 POSMay 29, 2024Offer documentSEC
S-8 POSMay 29, 2024Offer documentSEC
S-8 · Registration statement for employee plansMay 29, 2024Offer documentSEC
10-Q · Quarterly reportMay 8, 2024Quarterly reportSEC
8-K · Current reportMay 8, 2024ResultsSEC
4 · Change in ownershipMay 3, 2024Insider tradeSEC
4 · Change in ownershipMay 3, 2024Insider tradeSEC
4 · Change in ownershipMay 3, 2024Insider tradeSEC
4 · Change in ownershipMay 3, 2024Insider tradeSEC
ARS · Annual report to shareholdersApr 26, 2024Annual reportSEC
DEF 14A · Proxy statementApr 26, 2024Meeting noticeSEC
3 · Initial statement of ownershipApr 15, 2024Insider tradeSEC
4 · Change in ownershipApr 9, 2024Insider tradeSEC
4 · Change in ownershipApr 9, 2024Insider tradeSEC
4 · Change in ownershipApr 9, 2024Insider tradeSEC
4 · Change in ownershipApr 9, 2024Insider tradeSEC
4 · Change in ownershipMar 27, 2024Insider tradeSEC
4 · Change in ownershipMar 27, 2024Insider tradeSEC
4 · Change in ownershipMar 27, 2024Insider tradeSEC
4 · Change in ownershipMar 27, 2024Insider tradeSEC
8-K · Current reportMar 11, 2024Current reportSEC
4 · Change in ownershipFeb 27, 2024Insider tradeSEC
4 · Change in ownershipFeb 27, 2024Insider tradeSEC
4 · Change in ownershipFeb 27, 2024Insider tradeSEC
4 · Change in ownershipFeb 27, 2024Insider tradeSEC
10-K · Annual reportFeb 27, 2024Annual reportSEC
8-K · Current reportFeb 27, 2024ResultsSEC
SC 13G · Big-stake noticeFeb 14, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedFeb 13, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedFeb 9, 2024Big-stake noticeSEC
4 · Change in ownershipFeb 8, 2024Insider tradeSEC
3 · Initial statement of ownershipFeb 8, 2024Insider tradeSEC
8-K · Current reportJan 30, 2024Management or board changeSEC
SC 13G/A · Big-stake notice, amendedJan 26, 2024Big-stake noticeSEC
4 · Change in ownershipJan 9, 2024Insider tradeSEC
4 · Change in ownershipJan 9, 2024Insider tradeSEC
4 · Change in ownershipJan 9, 2024Insider tradeSEC
4 · Change in ownershipDec 15, 2023Insider tradeSEC
144 · Notice of proposed saleDec 15, 2023Other filingsSEC
4 · Change in ownershipNov 28, 2023Insider tradeSEC
4 · Change in ownershipNov 21, 2023Insider tradeSEC
4 · Change in ownershipNov 21, 2023Insider tradeSEC

This page holds 200 of 1,001 filings. Open Filings

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from ACADIA Pharmaceuticals Inc.’s releases · as of Oct 28, 2026

Common shares
172,828,972
Fully diluted
172,828,972

Fully diluted

LineSharesAs of
Common shares172,828,972Oct 28, 2026

Share count over time

CountShares
Oct 28, 2026172,828,972

Open Cap table

Shareholders

Institutions

HolderSharesOf the companyValueAs of
Baker Bros. Advisors LP42.9M24.8%US$865MSep 30, 2026
BlackRock22.9M13.3%US$462MSep 30, 2026
Vanguard16.4M9.5%US$330MSep 30, 2026
State Street7.65M4.4%US$154MSep 30, 2026
Rtw Investments, LP7.14M4.1%US$144MSep 30, 2026
Goldman Sachs4.62M2.7%US$93.1MSep 30, 2026
Geode Capital3.37M2.0%US$68MSep 30, 2026
Dimensional3.37M1.9%US$67.8MSep 30, 2026
Palo Alto Investors LP2.49M1.4%US$50.1MSep 30, 2026
Qube Research & Technologies Ltd2.46M1.4%US$49.7MSep 30, 2026
Show 50 holders
HolderSharesOf the companyValueAs of
Two Sigma2.19M1.3%US$44.2MSep 30, 2026
D. E. Shaw & Co., Inc.2.14M1.2%US$43MSep 30, 2026
Arrowstreet Capital, Limited Partnership2.13M1.2%US$42.9MSep 30, 2026
Citadel1.93M1.1%US$38.9MSep 30, 2026
Allspring Global Investments Holdings, LLC1.53M0.89%US$30.4MSep 30, 2026
Morgan Stanley1.48M0.86%US$29.8MSep 30, 2026
Frazier Life Sciences Management, L.P.1.44M0.83%US$29MSep 30, 2026
Northern Trust1.36M0.79%US$27.5MSep 30, 2026
Nuveen1.33M0.77%US$26.7MSep 30, 2026
Schwab1.31M0.76%US$26.5MSep 30, 2026
Allianz1.15M0.67%US$23.2MSep 30, 2026
Point72 Asset Management, L.P.1.14M0.66%US$22.9MSep 30, 2026
Renaissance Technologies1.11M0.64%US$22.3MSep 30, 2026
Bank of America1.01M0.58%US$20.3MSep 30, 2026
Rockefeller Capital Management L.P.1.01M0.58%US$20.3MSep 30, 2026
UBS975K0.56%US$19.6MSep 30, 2026
Panagora Asset Management Inc947K0.55%US$19.1MSep 30, 2026
Invesco889K0.51%US$17.9MSep 30, 2026
Principal857K0.50%US$17.3MSep 30, 2026
Millennium795K0.46%US$16MSep 30, 2026
Marshall Wace, LLP794K0.46%US$16MSep 30, 2026
BNY754K0.44%US$15.2MSep 30, 2026
Artisan Partners Limited Partnership724K0.42%US$14.6MSep 30, 2026
Fisher Asset Management, LLC711K0.41%US$14.3MSep 30, 2026
Ameriprise616K0.36%US$12.4MSep 30, 2026
Rice Hall James & Associates, LLC606K0.35%US$12.2MSep 30, 2026
Sun Life587K0.34%US$11.8MSep 30, 2026
Manufacturers Life Insurance Company, The551K0.32%US$11.1MSep 30, 2026
Public Sector Pension Investment Board545K0.32%US$10.1MSep 30, 2026
Trexquant Investment LP521K0.30%US$10.5MSep 30, 2026
AQR Capital Management LLC511K0.30%US$10.3MSep 30, 2026
Alyeska Investment Group, L.P.473K0.27%US$9.52MSep 30, 2026
RBC449K0.26%US$9.06MSep 30, 2026
Mackenzie413K0.24%US$8.32MSep 30, 2026
Franklin Templeton407K0.24%US$8.74MSep 30, 2026
Fred Alger Management, LLC393K0.23%US$7.91MSep 30, 2026
Y-Intercept (Hong Kong) Ltd383K0.22%US$7.71MSep 30, 2026
Hudson Bay Capital Management LP380K0.22%US$7.66MSep 30, 2026
Jupiter Asset Management LTD369K0.21%US$7.44MSep 30, 2026
Los Angeles Capital Management LLC361K0.21%US$7.27MSep 30, 2026

This page holds 50 of 343 holders. Open Shareholders

Funds

HolderSharesOf the companyValueAs of
iShares Core S&P Small-Cap ETF7.63M4.4%US$193MJun 30, 2026
Vanguard Total Stock Market Index Fund4.07M2.4%US$103MJun 30, 2026
State Street(R) SPDR(R) S&P(R) Biotech ETF3.98M2.3%US$101MJun 30, 2026
iShares Russell 2000 ETF3.35M1.9%US$84.7MJun 30, 2026
Vanguard Small-Cap Index Fund2.95M1.7%US$74.6MJun 30, 2026
Vanguard Small-Cap Growth Index Fund1.7M0.98%US$43MJun 30, 2026
Vanguard Extended Market Index Fund1.46M0.84%US$36.9MJun 30, 2026
Fidelity Small Cap Index Fund1.41M0.81%US$36.4MJul 31, 2026
iShares Biotechnology ETF1.2M0.69%US$30.3MJun 30, 2026
iShares Russell 2000 Growth ETF1.19M0.69%US$30.1MJun 30, 2026
Show 50 holders
HolderSharesOf the companyValueAs of
State Street(R) SPDR(R) Portfolio S&P 600(TM) Small Cap ETF1.17M0.67%US$29.5MJun 30, 2026
iShares S&P Small-Cap 600 Growth ETF1.14M0.66%US$28.8MJun 30, 2026
Artisan International Small-Mid Fund823K0.48%US$20.8MJun 30, 2026
Vanguard Tax-Managed Small-Cap Fund812K0.47%US$20.5MJun 30, 2026
State Street(R) SPDR(R) S & P 600(TM) Small Cap Growth ETF728K0.42%US$18.4MJun 30, 2026
Vanguard Strategic Equity Fund700K0.41%US$17.7MJun 30, 2026
Fidelity Extended Market Index Fund648K0.37%US$14MMay 31, 2026
Vanguard Russell 2000 Index Fund646K0.37%US$14MMay 31, 2026
U.S. Small Cap Portfolio638K0.37%US$16.5MJul 31, 2026
Schwab U.S. Small-Cap ETF600K0.35%US$13MMay 31, 2026
Dimensional U.S. Small Cap ETF559K0.32%US$14.5MJul 31, 2026
MFS New Discovery Value Fund550K0.32%US$11.9MMay 31, 2026
Nuveen Quant Small Cap Equity Fund541K0.31%US$14MJul 31, 2026
Vanguard Explorer Fund524K0.30%US$13.6MJul 31, 2026
College Retirement Equities Fund - Total Global Stock Account517K0.30%US$13.1MJun 30, 2026
U.S. Micro Cap Portfolio502K0.29%US$13MJul 31, 2026
Vanguard S&P Small-Cap 600 Index Fund433K0.25%US$9.38MMay 31, 2026
Small Cap Equity Portfolio432K0.25%US$11.2MJul 31, 2026
BlackRock Advantage Small Cap Core Fund411K0.24%US$8.9MMay 29, 2026
Small Cap Core Fund404K0.23%US$10.5MJul 31, 2026
Alger Weatherbie Specialized Growth Fund358K0.21%US$9.26MJul 31, 2026
Vanguard Health Care Index Fund357K0.21%US$7.73MMay 31, 2026
Dimensional U.S. Core Equity 2 ETF349K0.20%US$9.03MJul 31, 2026
Invesco Biotechnology & Genome ETF329K0.19%US$8.52MJul 31, 2026
Voya Small Cap Growth Fund329K0.19%US$7.13MMay 31, 2026
Schwab Small-Cap Index Fund313K0.18%US$8.1MJul 31, 2026
Columbia Variable Portfolio - Overseas Core Fund268K0.15%US$6.78MJun 30, 2026
Bridge Builder Small/Mid Cap Value Fund255K0.15%US$6.45MJun 30, 2026
Fidelity Total Market Index Fund237K0.14%US$5.13MMay 31, 2026
Master Small Cap Index Series236K0.14%US$5.98MJun 30, 2026
iShares U.S. Small-Cap Equity Factor ETF218K0.13%US$5.64MJul 31, 2026
JNL Small Cap Index Fund197K0.11%US$4.98MJun 30, 2026
Fidelity Series Total Market Index Fund193K0.11%US$4.18MMay 31, 2026
Columbia Small Cap Index Fund187K0.11%US$4.05MMay 31, 2026
Fidelity Enhanced Small Cap Core ETF186K0.11%US$4.7MJun 30, 2026
ALPS Medical Breakthroughs ETF176K0.10%US$3.81MMay 31, 2026
Vanguard Strategic Small-Cap Equity Fund174K0.10%US$4.39MJun 30, 2026
U.S. Small Cap Growth Portfolio171K0.10%US$4.43MJul 31, 2026
U.S. Core Equity 2 Portfolio169K0.10%US$4.36MJul 31, 2026
Principal U.S. Small-Cap ETF168K0.10%US$4.24MJun 30, 2026

This page holds 50 of 312 holders. Open Shareholders

Insider trades

TradeTradeSharesPriceValueDate
Schneyer Mark C.
Officer: EVP, CHIEF FINANCIAL OFFICER
Sale3,321USD 20.88US$69,342Oct 30, 2026
Schneyer Mark C.
Officer: EVP, CHIEF FINANCIAL OFFICER
Sale5,000USD 29.00US$145KAug 6, 2026
Schneyer Mark C.
Officer: EVP, CHIEF FINANCIAL OFFICER
Sale9,292USD 29.34US$273KAug 6, 2026
Schneyer Mark C.
Officer: EVP, CHIEF FINANCIAL OFFICER
Sale5,849USD 29.00US$170KAug 5, 2026
Thompson Elizabeth H.Z.
Officer: EVP, Head of Research & Dev
Sale16,508USD 26.13US$431KJul 30, 2026
Thompson Elizabeth H.Z.
Officer: EVP, Head of Research & Dev
Sale50USD 26.17US$1,309Jul 30, 2026
Kihara James
Officer: PRINCIPAL ACCOUNTING OFFICER
Sale11,421USD 26.08US$298KJun 26, 2026
Kihara James
Officer: PRINCIPAL ACCOUNTING OFFICER
Sale5,401USD 21.18US$114KMay 26, 2026
Kihara James
Officer: PRINCIPAL ACCOUNTING OFFICER
Sale1,332USD 21.79US$29,024May 4, 2026
Schneyer Mark C.
Officer: EVP, CHIEF FINANCIAL OFFICER
Sale3,506USD 21.79US$76,396May 4, 2026
All 12 trades
TradeTradeSharesPriceValueDate
Kihara James
Officer: PRINCIPAL ACCOUNTING OFFICER
Sale1,030USD 22.20US$22,866Apr 7, 2026
Schneyer Mark C.
Officer: EVP, CHIEF FINANCIAL OFFICER
Sale2,709USD 22.20US$60,140Apr 7, 2026

Big stakes

StakeStakeSharesDateFiling
Julian C. Baker25.40%43.3MFeb 24, 2026Schedule 13D
BlackRock, Inc.11.90%19.9MJan 31, 2025Schedule 13G
Vanguard Portfolio Management LLC5.15%8.78MMar 31, 2026Schedule 13G

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Felix Baker
Other companies: BeOne Medicines Ltd. Class A (Director · Since at least Nov 6, 2026); Denali Therapeutics Inc. (Director · Since at least Jun 3, 2025); Replimune Group, Inc. (Director · Since at least Mar 5, 2025); Bicycle Therapeutics PLC (Director · Since at least Apr 18, 2024); Kymera Therapeutics, Inc. (Chairman · Since at least Mar 28, 2024); vTv Therapeutics Inc. (Director · Since at least Feb 27, 2024); Madrigal Pharmaceuticals, Inc. (Director · Since at least Jun 15, 2023); TScan Therapeutics, Inc. (Director · Since at least Jul 15, 2021); DBV Technologies SA (Director · Since at least Jan 1, 2021); Prelude Therapeutics Incorporated (Director · Since at least Mar 27, 2020); IGM Biosciences Inc (Director · Since at least Sep 17, 2019); Kodiak Sciences Inc (Director · Since at least Oct 3, 2018); Kiniksa Pharmaceuticals International, plc (Lead Director · Since at least Feb 9, 2018); Incyte Corporation (Director · Since at least Jan 4, 2008); Immunocore Holdings plc (Director · May 28, 2024 – May 15, 2025 · Past); Spyre Therapeutics, Inc. (Director · Feb 23, 2021 – Jun 8, 2021 · Past); Talis Biomedical Corp (Director · Nov 2, 2020 – Jun 9, 2023 · Past); Zymeworks Inc. (Director · Mar 16, 2020 – May 8, 2020 · Past); Neurogene Inc. (Director · May 8, 2017 – Dec 18, 2023 · Past); Alexion Pharmaceuticals Inc (Director · Jun 22, 2015 – May 14, 2020 · Past); Aceragen Inc. (Director · Mar 10, 2014 – Apr 1, 2019 · Past); Ardea Biosciences Inc (Director · Feb 8, 2010 – Jun 19, 2012 · Past); Synageva BioPharma Corp (Director · Aug 14, 2007 – Jun 22, 2015 · Past); Neurogen Corp (Director · Jun 7, 2007 – Jul 25, 2008 · Past); Seagen Inc (Director · May 25, 2007 – Dec 14, 2023 · Past); Genomic Health Inc (Director · May 21, 2007 – Oct 1, 2019 · Past)
Director · Since at least Jan 18, 2013
Laura Brege
Other companies: Edgewise Therapeutics, Inc. (Director · Since at least Mar 25, 2021); Mirum Pharmaceuticals, Inc. (Board Member · Since at least Jul 17, 2019); Pacira BioSciences, Inc. (Director · Since at least Jun 6, 2016); Aratana Therapeutics Inc (Director · Jun 24, 2016 – Jul 27, 2018 · Past); Portola Pharmaceuticals Inc (Director · Jun 17, 2016 – Jul 2, 2020 · Past); Dynavax Technologies Corporation (Director · May 31, 2016 – May 30, 2019 · Past)
Director · Since at least Jun 10, 2016
Elena Ridloff
Other companies: Immunic, Inc. (Director · Since at least Aug 6, 2026); Sionna Therapeutics, Inc. (CFO and CBO · Since at least Feb 6, 2025); Kymera Therapeutics, Inc. (Director · Since at least Mar 12, 2021); Kronos Bio Inc (Director · Since at least Oct 8, 2020)
EVP and CFO · Jan 6, 2021 – Apr 29, 2021 · Past
James Daly
Other companies: Halozyme Therapeutics, Inc. (Director · Since at least Oct 1, 2026); Cytokinetics, Incorporated (Director · Since at least Aug 19, 2025); Madrigal Pharmaceuticals, Inc. (Director · Since at least Jun 20, 2025)
Director · Since at least May 29, 2025
Michael Yang
Other companies: Ionis Pharmaceuticals, Inc. (Director · Since at least Dec 14, 2023); Pacira BioSciences, Inc. (Director · Since at least Oct 6, 2023); Akcea Therapeutics Inc (Director · Sep 20, 2019 – Oct 12, 2020 · Past)
EVP and CCO · Apr 18, 2018 – Jan 6, 2021 · Past
Douglas J. Williamson
Other companies: Vistagen Therapeutics, Inc. (Director · Since at least Jul 29, 2026); Avadel Pharmaceuticals PLC (Chief Medical Officer · Feb 14, 2022 – Feb 14, 2022 · Past)
Executive VP, Research & Dev · Feb 1, 2023 – Feb 10, 2023 · Past
Adora Ndu
Other companies: DBV Technologies SA (Board Member · Since at least Nov 5, 2026)
Director · Since at least May 29, 2026
Edmund Harrigan
Other companies: Incyte Corporation (Director · Since at least Oct 2, 2026)
Director · Since at least Jun 1, 2026
Elizabeth H Z Thompson
Other companies: IGM Biosciences Inc (Director · Since at least Oct 3, 2023)
EVP, Head of Research & Dev · Since at least Apr 4, 2024
Jonathan M. Poole
Other companies: Evelo Biosciences, Inc. (CFO · May 8, 2018 – Jan 28, 2020 · Past)
Director · Since at least Mar 3, 2026
All 25 people
PersonSeat
Julian Baker
Other companies: Incyte Corporation (Managing Partner, Baker Brothers Investments | Chairman, Incyte · Since at least Dec 12, 2025)
Director · Since at least Nov 5, 2026
Stephen Biggar
Other companies: Kiniksa Pharmaceuticals International, plc (Director · Since at least Nov 5, 2026)
Chairman · Since at least Mar 3, 2026
Thomas Garner
Other companies: Lexicon Pharmaceuticals, Inc. (SVP, Chief Commercial Officer · Oct 9, 2023 – Feb 8, 2024 · Past)
EVP, Chief Commercial Officer · Since at least Dec 9, 2024
Thomas H Aasen
Other companies: Avalo Therapeutics, Inc. (Director · Jan 10, 2016 – Jun 30, 2017 · Past)
EXEC VP, CFO AND CBO · May 9, 2007 – Apr 4, 2014 · Past
Uli Hacksell
Other companies: Avalo Therapeutics, Inc. (Director · Oct 14, 2015 – Mar 31, 2020 · Past)
CEO, Director · May 16, 2007 – Feb 17, 2015 · Past
Austin D KimEVP,General Counsel, Secretary · Jul 18, 2018 – Jan 6, 2024 · Past
Carl SegerstromChief People Officer · Since at least Jul 6, 2026
Catherine Owen AdamsChief Executive Officer · Since at least Sep 28, 2026
Elizabeth GarofaloDirector · Since at least Jun 1, 2026
Glenn BaityEVP AND GC · Oct 4, 2017 – Apr 18, 2018 · Past
James KiharaPRINCIPAL ACCOUNTING OFFICER · Since at least Jun 23, 2020
Jennifer J. RhodesChief Legal Officer and Secretary · Since at least Nov 4, 2026
Konstantina KatchevesChief Business and Strategy Officer · Since at least Nov 5, 2025
Mark SchneyerEVP, CHIEF FINANCIAL OFFICER · Since at least Apr 5, 2025
Scott CenciChief Information and Data Officer · Since at least Aug 4, 2025

Open People

Log in to ask 6ix AI your own questions about ACADIA Pharmaceuticals Inc.